JNJ Factor-Based Stock Analysis

Validea's guru fundamental report assigns Johnson & Johnson (JNJ) an 88% rating based on Partha Mohanram's P/B Growth Investor model, which identifies low book-to-market stocks with characteristics for sustained future growth. This strong rating indicates significant interest in the large-cap biotechnology and drugs stock, suggesting JNJ's fundamentals align well with a strategy known for separating outperforming growth companies from underperformers.

Analysis

Johnson & Johnson (JNJ) receives a high rating of 88% based on Validea's P/B Growth Investor model, a quantitative strategy from Partha Mohanram designed to identify low book-to-market stocks with indicators of sustained future growth. This score, which approaches the 90% threshold for 'strong interest', highlights the large-cap biotechnology firm's favorable fundamentals. The company passes on eight of the nine criteria evaluated, demonstrating strength in profitability (Return on Assets), cash generation (Cash Flow from Operations to Assets), and operational stability (low variance in ROA and sales). The model's criteria are specifically designed to separate high-performing growth stocks from underperformers. The single point of failure in the assessment is the 'Research and Development to Assets' metric, which suggests R&D expenditure does not meet the model's threshold relative to the company's asset base.

Key Decisions for Investors

• Given the strong 88% rating and positive signals on profitability and cash flow, growth-oriented investors should view this as a quantitative validation of JNJ's fundamental strength.
• It is crucial to conduct further due diligence on the single failing metric, 'Research and Development to Assets', to understand if this represents a strategic risk to the innovation pipeline or is a benign characteristic of JNJ's large scale.
• This analysis is most applicable for investors employing a quality growth or Growth at a Reasonable Price (GARP) framework, as the underlying model specifically targets undervalued growth companies rather than deep-value or high-momentum stocks.